	e for form 1449A		· · ·		or information unless it contains a valid OMB control number	
INFORMATION DISCLOSURE			JRE	Complete if Known		
STATEMENT BY APPLICANT			NT	Application Number	10534773	
				Filing Date	May 13, 2005	
				First Named Inventor	ROBERTSON, John	
				Art Unit	1643	
				Examiner Name	Lynn Anne Bristol	
(L	Use as many she	ets as necessary)				
	<u> </u>					
Sheet	1	of	1	Attorney Docket No: 49409-315804		

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup>	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
/L.B./		20030099639	May 29, 2003	Rikihisa, Y. et al.		
ĕ		20050084904	Apr 21, 2005	Laal, S. et al.		
000		20050276485	Dec 15, 2005	Mori, A.		
00000		20070224174	Sep 27, 2007	Kang, H. S., et al.		
		6280962	Aug 28, 2001	Cohen, T. J.		
$\overline{V}$		6667160	Dec 23, 2003	Fine, K. D.		

FOREIGN PATENT DOCUMENTS							
	Examiner Initials*	Cite No	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup>	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>

NON PATENT LITERATURE DOCUMENTS					
Examiner Cite Initials* No <sup>1</sup>		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
/L.B./ "National Library of Medicine C Web", April 23, 2009		"National Library of Medicine Gateway MeSH term definition downloaded from the Web", April 23, 2009			
Secretor		CANEVARI, et al., "1975-1995 Revised anti-cancer serological response: Biological significance and clinical implications", Annals of Oncology 1996, Vol. 7, pp. 227-232			
000000000000000000000000000000000000000		LUBIN, et al., "Analysis of p53 Antibodies in Patients with Various Cancers Define B-Cell Epitopes of Human p53: Distribution on Primary Structure and Exposure on Protein Surface", Cancer Research 1993, Vol. 53, pp. 5872-5876			
000000000000000000000000000000000000000		MOINGEON, "Strategies for designing vaccines eliciting Th1 responses in humans", Journal of Biotechnology 2002, Vol. 98, pp. 189-198			
<b>Y</b>		O'SULLIVAN, et al., "Polymorphic epithelial mucin from the sera of advanced breast cancer patients - isolation and partial characterisation", British Journal of Cancer 1990, Vol. 61, pp. 801-808			

EXAMINER	/Lynn Bristol/	DATE CONSIDERED	12/05/2009
EXAMINER	/Lynn Bristol/	DATE CONSIDERED	12/05/2

<sup>•</sup> EXAMINER; Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant: Applicant's unique citation designation number (optional) See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901 04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must preced the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 ii possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O., Box 1450, Alexandria, VA 22313-1450.